Evidence map›Paper›PMID 34013273›Full record

ArticlebioRxiv : the preprint server for biology2021

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

M Gordon Joyce, Wei-Hung Chen, Rajeshwer S Sankhala, Agnes Hajduczki, Paul V Thomas, Misook Choe, William Chang, Caroline E Peterson, Elizabeth Martinez, Elaine B Morrison and 48 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

58 authors at 6 institutions in 1 country.

M Gordon JoyceEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Wei-Hung ChenEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Rajeshwer S SankhalaEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Agnes HajduczkiEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Paul V ThomasEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Misook ChoeEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
William ChangEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Caroline E PetersonEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Elizabeth MartinezEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Elaine B MorrisonU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Clayton SmithCenter for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Aslaa AhmedViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Lindsay WieczorekHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Alexander AndersonHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Rita E ChenDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.
James Brett CaseDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.
Yifan LiHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Therese OertelHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Lorean RosadoHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Akshaya GaneshHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Connor WhalenHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Joshua M CarmenU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Letzibeth Mendez-RiveraHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Christopher KarchHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Neelakshi GohainHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Zuzana VillarHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
David McCurdyHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Zoltan BeckHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Jiae KimHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Shikha ShrivastavaHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Ousman JobeHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Vincent DussuptHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Sebastian MolnarHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Ursula TranHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Chandrika B KannadkaHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Michelle ZemilHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Htet KhanhCenter for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Weimin WuCenter for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Matthew A ColeTrudeau Institute, Inc., Saranac Lake, NY, USA.
Debra K DusoTrudeau Institute, Inc., Saranac Lake, NY, USA.
Larry W KummerTrudeau Institute, Inc., Saranac Lake, NY, USA.
Tricia J LangTrudeau Institute, Inc., Saranac Lake, NY, USA.
Shania E MuncilTrudeau Institute, Inc., Saranac Lake, NY, USA.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Shelly J KrebsHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Victoria R PolonisU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Saravanan RajanAntibody Discovery and Protein Engineering (ADPE), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
Patrick M McTamneyMicrobial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Mark T EsserMicrobial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
William W ReileyTrudeau Institute, Inc., Saranac Lake, NY, USA.
Morgane RollandHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Natalia de ValCenter for Molecular Microscopy, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO 63110, USA; The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO 63110, USA.
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Gary R MatyasU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Mangala RaoU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Nelson L MichaelCenter for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Kayvon ModjarradEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Henry M. Jackson Foundation · USWalter Reed Army Institute of Research · USTrudeau Institute · USLeidos (United States) · USAstraZeneca (United States) · USWashington University in St. Louis · US

Funding

Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
NIAID NIH HHS R01 AI157155
6 · The paper itself

Abstract

The need for SARS-CoV-2 next-generation vaccines has been highlighted by the rise of variants of concern (VoC) and the long-term threat of other coronaviruses. Here, we designed and characterized four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and RBD. These immunogens induced robust S-binding, ACE2-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice. A Spike-ferritin nanoparticle (SpFN) vaccine elicited neutralizing titers more than 20-fold higher than convalescent donor serum, following a single immunization, while RBD-Ferritin nanoparticle (RFN) immunogens elicited similar responses after two immunizations. Passive transfer of IgG purified from SpFN- or RFN-immunized mice protected K18-hACE2 transgenic mice from a lethal SARS-CoV-2 virus challenge. Furthermore, SpFN- and RFN-immunization elicited ACE2 blocking activity and neutralizing ID50 antibody titers >2,000 against SARS-CoV-1, along with high magnitude neutralizing titers against major VoC. These results provide design strategies for pan-coronavirus vaccine development. HIGHLIGHTS: Iterative structure-based design of four Spike-domain Ferritin nanoparticle classes of immunogensSpFN-ALFQ and RFN-ALFQ immunization elicits potent neutralizing activity against SARS-CoV-2, variants of concern, and SARS-CoV-1Passively transferred IgG from immunized C57BL/6 mice protects K18-hACE2 mice from lethal SARS-CoV-2 challenge.

Identifiers

PMID34013273
PMCPMC8132231
OpenAlexW3162440848

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.